Elaboration of a new synovial predictive score of septic origin for acute arthritis on the native joint (RESAS).


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
14 05 2021
Historique:
received: 11 04 2020
revised: 21 07 2020
pubmed: 17 11 2020
medline: 30 6 2021
entrez: 16 11 2020
Statut: ppublish

Résumé

To establish a new predictive score for the diagnosis of septic arthritis (SA) according to different synovial fluid (SF) variables. First, we analysed the different clinical, biological and SF variables associated with the diagnosis of SA (according to the Newman's criteria) in a monocentric cohort of acute arthritis (<30 days) (n = 233) (SYNOLACTATE cohort). A new score predictive of SA (RESAS) was created using the independent discriminant variables after multivariate analysis. A value was attributed to each variable of the score according to the weighting based on their likelihood ratio for the diagnosis of SA. RESAS performance was then tested on the first cohort (internal validation) and then checked on a second independent cohort (n = 70) (external validation). After multivariate analysis, four independent variables of the SF were included for RESAS: (i) purulent SF or white blood cells count ≥70 000/mm3; (ii) absence/presence of crystals; (iii) lactate; and (iv) glucose synovial level. RESAS ranged between -4 and +13 points. The performance of RESAS to predicted SA was excellent with area under the curve (AUC)=0.928 (0.877-0.980) in internal validation and AUC=0.986 (0.962-1.00) in external validation. For a RESAS threshold ≥+4, SA was diagnosed with Se=56.0% (0.371-0.733), Sp=98.1% (0.952-0.993), LR+=29.1 (10.4-81.6) in the first cohort and with Se=91.7% (0.646-0.985), Sp=98.3% (0.909-0.997), LR+=53.2 (7.56-373) in the second cohort. RESAS is a new composite score of four SF variables with excellent performance to predicted SA in acute arthritis population.

Identifiants

pubmed: 33197255
pii: 5983717
doi: 10.1093/rheumatology/keaa567
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2238-2245

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Guillaume Coiffier (G)

Rheumatology Department, CHU Rennes.
U1241, CIMIAD Unit, INSERM.

Olivia Berthoud (O)

Rheumatology Department, CHU Rennes.

Jean David Albert (JD)

Rheumatology Department, CHU Rennes.
U1241, CIMIAD Unit, INSERM.

François Robin (F)

Rheumatology Department, CHU Rennes.
U1241, CIMIAD Unit, INSERM.

Claire Goussault (C)

Rheumatology Department, CHU Rennes.

Anne Gougeon-Jolivet (A)

U1241, CIMIAD Unit, INSERM.
Bacteriology Department.

Claude Bendavid (C)

U1241, CIMIAD Unit, INSERM.
Biochemistry Department, CHU Rennes, University of Rennes 1, Rennes, France.

Pascal Guggenbuhl (P)

Rheumatology Department, CHU Rennes.
U1241, CIMIAD Unit, INSERM.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH